AN OPEN LABEL STUDY OF POSTMENOPAUSAL WOMEN WITH OESTROGEN RECEPTOR POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER TREATED WITH EVEROLIMUS (RAD001) WITH EXEMESTANE, WITH EXPLORATORY EPIGENETIC MARKER ANALYSIS: